SK Biopharmaceuticals向美国子公司SK Life Science供应715.9亿韩元cenobamate(XCOPRI)，系合并抵消的内部关联交易

SK Biopharmaceuticals Supplies 71.6 Billion Won of Cenobamate to U.S. Unit - Seoul Economic Daily
Skip to main content
Seoul Economic Daily
Seoul Economic Daily
KST
Seoul Economic Daily
Korea's Leading Business News Since 1960
한국어
Menu
Saved Articles
Newsletters
AI KEY
Settings
|
Summary
|
Save
A
A
A
Interior view of SK Biopharmaceuticals' Pangyo headquarters. Photo courtesy of SK Biopharmaceuticals
SK Biopharmaceuticals (326030.KS) will supply about 71.6 billion won ($51.5 million) worth of cenobamate, its epilepsy drug sold under the brand name XCOPRI, to its U.S. subsidiary for sale in the American market.
The company said in a regulatory filing on the 14th that it had signed a pharmaceutical supply contract worth 71.59316 billion won with SK Life Science, its U.S. arm. The amount equals 10.1% of SK Biopharmaceuticals' consolidated revenue of 706.74096 billion won last year.
Under the contract, SK Biopharmaceuticals will supply the product to SK Life Science for sale in the U.S. market. The contract runs from that day through the 18th. There is no down payment or advance payment, and SK Life Science will pay within 120 days of delivery.
SK Life Science is SK Biopharmaceuticals' U.S. subsidiary and handles sales of cenobamate in the United States. Under the structure, SK Biopharmaceuticals develops and manufactures the drug while its U.S. unit sells it locally.
Because the transaction is an intercompany deal between SK Biopharmaceuticals and SK Life Science, however, it will not be recognized as revenue on a consolidated basis.
#
SKBiopharmaceuticals
#
Cenobamate
#
XCOPRI
#
SKLifeScience
#
Epilepsy
#
KoreaPharma
Original reporting by
Park Woo-in
for Seoul Economic Daily.
AI-translated from Korean. Quotes from foreign sources are based on Korean-language reports and may not reflect exact original wording.
Translated by AI on
Sep 14, 2026
View Korean original
↗
Translation Policy
Watch · Seoul Economic Daily
More →
2:20
KB Securities Sees Samsung Back at No.1, SK Hynix at No.3 Next Year | September 14 2026 | Securities Daily
2:20
Most Read This Week
1
-
5
‹
›
1
JBL Launches Xtreme 5 Bluetooth Speaker With Stronger Bass
2
Hyundai, POSCO Break Ground on $5.8 Billion U.S. Steel Mill
3
China Pumps 300 Billion Yuan Into Eight Financial Firms
4
Korea to Offer 20,000 Homes at 1,000 Won a Day for Young Adults
5
Samsung, SK hynix Memory Stockpiles Fall Below 10 Days
← Back to Home
AI KEY
Preview
↗
Korean Corporate Intelligence Hub
KOSPI · KOSDAQ · 12 sectors
A live, cap-weighted view of every KOSPI and KOSDAQ sector, with same-day Korean reporting distilled by company — built for foreign investors, correspondents and analysts who need to scan Korea before the next session.
Click to explore AI KEY
→
Open AI KEY in full screen
↗
Korea Company Atlas
Preview
↗
Market Ontology · The Feedback Loop
KFTC 2025 · 92 groups · 121,954 articles
An English ontology of the Korean market — how companies, the media, the government and the National Assembly move each other in a loop. Korea's named controlling persons and designated business groups are a mechanism, not a risk to be priced blind.
Click to explore the atlas
→
Open Atlas in full screen
↗
SIGNAL
Now live
↗
English Edition · Capital Markets
M&A · IPO · PE · Fund Flows
SIGNAL English Edition is live — Korea's deal desk reporting in English. M&A, IPOs, private equity and fund flows, covered daily for global institutional investors. Browse free; subscriber-only scoops at the 50% intro rate.
Click to explore SIGNAL
→
Open SIGNAL in full screen
↗